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CD95 ligand (CD95L) is expressed by immune cells
and triggers apoptotic death. Metalloprotease-
cleaved CD95L (cl-CD95L) is released into the blood-
stream but does not trigger apoptotic signaling.
Hence, the pathophysiological role of cl-CD95L re-
mains unclear. We observed that skin-derived endo-
thelial cells from systemic lupus erythematosus (SLE)
patients expressed CD95L and that after cleavage,
cl-CD95L promoted T helper 17 (Th17) lymphocyte
transmigration across the endothelial barrier at the
expense of T regulatory cells. T cell migration relied
on a direct interaction between the CD95 domain
called calcium-inducing domain (CID) and the Src
homology 3 domain of phospholipase Cg1. Th17
cells stimulated with cl-CD95L produced sphingo-
sine-1-phosphate (S1P), which promoted endothelial
transmigration by activating the S1P receptor 3.
We generated a cell-penetrating CID peptide that
prevented Th17 cell transmigration and alleviated
clinical symptoms in lupus mice. Therefore, neutral-
izing the CD95 non-apoptotic signaling pathway
could be an attractive therapeutic approach for SLE
treatment.Immunity 45, 209–223,
This is an open access article undINTRODUCTION
CD95 ligand (CD95L, also known as FasL) is a transmembrane
glycoprotein that acts locally through cell-to-cell contact (Suda
et al., 1993). The extracellular domain of CD95L comprises a jux-
tamembrane stalk region (Orlinick et al., 1997) that is cleavable
by metalloproteases (Fouque´ et al., 2014), and this cleavage
releases CD95L into the bloodstream. CD95 (also known as
Fas, APO-1, and TNFRSF6) belongs to the tumor necrosis factor
receptor (TNF-R) family and is ubiquitously expressed in
the body (Peter et al., 2015). When membrane-bound CD95L
binds to CD95, the intracellular region of CD95 (designated the
death domain [DD]) orchestrates the formation of a death-
inducing signaling complex (DISC) by recruitment of the adaptor
molecule, Fas-associated protein with death domain (FADD),
which in turn induces caspase-8 aggregation and subsequent
apoptosis (Kischkel et al., 1995). By contrast, we and others
have shown that metalloprotease-cleaved CD95L (cl-CD95L)
promotes formation of an atypical molecular complex desig-
natedmotility-inducing signaling complex (MISC) that stimulates
non-apoptotic signaling pathways and increases intracellular
calcium (Ca2+) content (Kleber et al., 2008; Malleter et al.,
2013; Tauzin et al., 2011).
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disorder of largely unknown etiology; its pathogenesis can affect
almost all organs and tissues. Human studies andmurinemodels
indicate a role for IL-17-producing T helper 17 (Th17) cells in SLEJuly 19, 2016 ª 2016 The Author(s). Published by Elsevier Inc. 209
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
progression (see (Shin et al., 2011) for a review). Lupus-prone
mice are partially protected from immunopathology by a reduc-
tion in renal Th17 cell accumulation (Steinmetz et al., 2009).
Therefore, abnormal Th17 cell trafficking to inflamed organs
might promote SLE pathogenesis, and modulation of Th17 cell
migration is an attractive therapeutic option for reducing dis-
ease-related inflammation. However, the precise mechanism
of Th17 cell accumulation in damaged SLE organs remains
unclear.
A close relationship exists between SLE pathogenesis and
deregulation of CD95 signaling already. Patients suffering from
autoimmune lymphoproliferative syndrome (ALPS) type Ia har-
bor CD95 mutations responsible for lymphoproliferation and
SLE-like autoimmunity (Drappa et al., 1996; Fisher et al., 1995;
Rieux-Laucat et al., 1995). These ALPS type Ia patients show
heterozygous mutations (Straus et al., 2001) that lead to the in-
hibition of the CD95-mediated apoptotic signal without affecting
activation of non-apoptotic signaling pathways (Legembre et al.,
2004). Accordingly, we hypothesize that aggravation of lupus
symptoms is caused not only by a defective apoptotic process
(Ku¨htreiber et al., 2003) but also by induction of CD95-mediated
non-apoptotic signaling pathways.
Herein, we demonstrate that high concentrations of cl-CD95L
in SLE patients promoted Th17 cell migration across the endo-
thelial barrier at the expense of regulatory T (Treg) cells in a
Ca2+-dependent manner. This CD95-mediated Ca2+ signaling
occurred independently of the CD95-DD; exploiting this result,
we designed a therapeutic molecule that selectively neutralized
the CD95-mediated non-apoptotic signaling pathways. More-
over, in a murine model of SLE, this treatment halted the pro-in-
flammatory actions of cl-CD95L, alleviating both immune and
pathological hallmarks of SLE.
RESULTS
CD95L in SLE Serum Promotes Endothelial
Transmigration of Activated Th17 Cells
Soluble CD95L concentrations in serum obtained from SLE pa-
tients were higher than those from age-matched healthy donors
(Figure 1A). SLE serum was fractionated by size-exclusion chro-
matography (Figure 1B). By ELISA, CD95L was mainly detected
in fractions 76–78; the proteins in these fractions showedmolec-
ular masses ranging from 75 to 80 kDa under native conditions.
Next, CD95L was immunoprecipitated from these fractions, and
denaturing conditions revealed a polypeptide band of 26 kDa
(Figure 1B). These results do not rule out the possibility that
soluble CD95L is associated with another partner but do strongly
suggest that serum CD95L in SLE patients corresponds to a
homotrimeric ligand.
We next hypothesized that if serum CD95L contributes to in-
flammatory processes in SLE patients by promoting extravasa-
tion of Th17 cells in inflamed tissues, then CD95L-expressing
cells should be detected in these tissues and surrounded by
IL-17-expressing cells. Therefore, we performed an immuno-
histochemical analysis of skin biopsies obtained from SLE pa-
tients to examine the distribution of CD95L- and IL-17-express-
ing cells. Skin biopsies from SLE patients, but not from healthy
controls, showed positive staining for CD95L and IL-17 (Fig-
ure 1C and Figure S1 in the Supplemental Information available210 Immunity 45, 209–223, July 19, 2016online). CD95L expression was mainly restricted to blood-
vessel endothelial cells, and these cells were surrounded by
infiltrating immune cells (Figure 1C and Figure S1). Serial slices
of skin biopsies from SLE patients revealed that IL17 was
co-expressed by CD4+ T cells (Figure 1D), indicating that
CD95L-expressing blood vessels were surrounded by infil-
trating Th17 cells. Moreover, a densitometric analysis of
stained tissues from lupus patients (n = 10) revealed a correla-
tion between CD95L concentrations and the number of tissue-
infiltrating, IL-17-expressing immune cells (Figure 1E). This
suggested that CD95L might behave as a chemoattractant for
Th17 cells.
To examine whether after cleavage by metalloproteases, sol-
uble CD95L had a chemoattractive effect on all T cells or was
selective for distinct Th cell subsets, we next evaluated transmi-
gration of undifferentiated (Th0) and differentiated (Th1 and
Th17) CD4+ T cells with or without serum from SLE patients.
Compared with healthy serum, SLE serum triggered a moderate
increase in Th1 cell transmigration and a marked increase
in Th17 cell transmigration (Figure 1F). Pre-incubation of SLE
serumwith a decoy CD95 receptor (CD95-Fc) dose dependently
inhibited Th17 cell migration, indicating that transmigration of
these cells relied on CD95 signaling (Figure 1G).
We produced a homotrimeric, metalloprotease-cleaved
version of human CD95L (cl-CD95L) (Tauzin et al., 2011). Similar
to CD95L in SLE serum, cl-CD95L more efficiently promoted the
transmigration of Th1 and Th17 lymphocytes relative to undiffer-
entiated Th0 and differentiated Th2 cells (Figure 1H). Because
an imbalance between the Th17/Treg cell ratio in inflamed or-
gans has been previously reported in the pathogenesis of SLE
and other autoimmune disorders (Yang et al., 2009), we also
examined the effect of cl-CD95L on Treg cell transmigration.
Cl-CD95L increased the endothelial transmigration of in-vitro-
differentiated Th17 cells, but not that of Treg cells (Figure 1I).
These results support the idea vthat high concentrations of
serum CD95L in SLE patients can cause pro-inflammatory
Th17 cell accumulation and destabilize Th17/Treg cell balance
in diseased organs.
To determine the mechanism responsible for this preferential
transmigration of Th17 cells, we examined the expression of
adhesion molecules known to promote endothelial transmigra-
tion. Cl-CD95L had no effect on the expression concentrations
of adhesion molecules expressed by human umbilical-vein
endothelial cells (HUVECs) (Figure S1B). On the other hand,
although stimulation of Th17 cells with cl-CD95L had no effect
on the amount of lymphocyte function-associated antigen-1
(LFA-1, the ICAM-1 binding partner), it led to upregulation of
P-selectin glycoprotein-1 (PSGL-1, an E-/P-selectin ligand) (Fig-
ure S1C). The concentration of PSGL-1 was also upregulated in
Th1 cells but to a lesser extent than in Th17 cells, and it tended
to be downregulated in Treg cells (Figure S1C). Because
HUVECs used in our transmigration assay expressed E-selectin
but not P-selectin (Figure S1B), we next examined whether
blocking these E-selectin-PSGL-1 interactions could abrogate
the CD95-mediated Th17 transmigration. An E-selectin-neutral-
izing monoclonal antibody (mAb) inhibited Th17 cell transmigra-
tion but did not affect the weak endothelial transmigration
observed in Treg cells exposed to cl-CD95L (Figure S1D). This
antibody was more effective in preventing the CD95-mediated
Figure 1. Serum CD95L in SLE Patients Induces Transmigration of T Lymphocytes
(A) Soluble CD95L levels were measured in serum from newly diagnosed SLE patients (n = 34) and healthy donors (n = 8) via ELISA (Student’s t test).
(B) CD95L in SLE serum was fractionated by size-exclusion column chromatography and measured via ELISA. Inset: CD95L was immunoprecipitated from gel-
filtration fractions 40–46 and 76–78 and subjected to immunoblotting. The image is representative of gel-filtration analysis of four different patients.
(C) CD95L and IL-17 staining in inflamed skin samples from lupus patients or healthy mastectomy subjects. Numbers represent different patients. The scale bar
represents 100 mm.
(D) CD95L, CD31, CD4, and IL-17 staining in inflamed skin samples from an SLE patient. ‘‘V’’ represents an endothelial vessel, and arrowheads identify marker-
expressing cells.
(E) Densitometric analysis of CD95L and IL-17 staining in different patients.
(F) Transmigration of human T cell subpopulations in the presence of serum from SLE patients or healthy donors.
(G) Th17 T cell transmigration in the presence of SLE serum containing the indicated concentrations of CD95-Fc. Undifferentiated Th0 T cells served as controls.
Data represent means ± SD of five individual serum donors.
(H) CD4+ T cell transmigration with or without cl-CD95L (100 ng/mL). Data represent means ± SD of three independent experiments.
(I) Treg and Th17 cell transmigration with or without cl-CD95L (100 ng/mL) Data represent means ± SD of three independent experiments (two-way ANOVA).
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endothelial transmigration of Th17 cells than of Th1 cells (Fig-
ure S1D). To understand why Th1 cells responded less efficiently
to cl-CD95L than Th17 cells, we compared the quantity of CD95
in different Th subsets from 20 blood donors. Although the
amount of CD95 was not lower in Treg cells than in Th17 cells
(Figure S1E), Th1 cells exhibited a lower concentration of CD95
than did Th17 cells (Figure S1E). This finding might then explain
why, in the presence of cl-CD95L, Th1 cells migrated with a
lower intensity than Th17 cells.
Toaddress howcl-CD95Lselectively promoted theendothelial
transmigration of Th17 cells to the detriment of Treg cells, we
investigated howcl-CD95L stimulation affected the gene expres-
sion profile of Th17 and Treg cells. Human Th17 cells (CD4+
CXCR3CCR6+CD45RA) andTregcells (CD4+CD127lowCD25+)
were sorted from the blood of two different donors (Figure S1F)
and stimulated in the presence or absence of cl-CD95L. Tran-
scriptomic signatures of Treg and Th17 cells stimulated with
cl-CD95L were analyzed (Figures 2A and 2B and Tables S1 and
S2). Gene ontology analysis revealed that the sphingosine 1
phosphate (S1P) signaling pathway was modulated in Th17
cells stimulated with cl-CD95L (Figure 2C), whereas Treg cells
exposed to cl-CD95L showed overexpression of genes respon-
sible for the implementation of cell death (Figure 2C). The S1P
signaling pathway (Figure S1G) can promote endothelial transmi-
gration of activated T and B lymphocytes, leading to extra- or in-
travasation. Using Th17andTreg cells sorted as aforementioned,
we confirmed that cl-CD95L promoted endothelial transmigra-
tion of Th17 cells but not Treg cells (Figure 2D). Pre-incubation
of Th17 cells with FTY720, a chemical that induces internalization
of four S1P receptors (S1P-1, -3, -4, and -5) (Brinkmann et al.,
2002) indicated that cl-CD95L selectively promoted endothelial
transmigration of Th17 cells by stimulating the S1P signaling
pathway (Figure 2D). To evaluate the role of S1PR3 in the
CD95-mediated Th17 transmigration, we next tested the effect
of additional antagonist molecules, namely TY-52156 (Murakami
et al., 2010), CAY-1044, VPC-23019, and W-146 (Li et al., 2015)
(Figure 2D), on Th17 cell migration. Although the selective
S1PR3 inhibitors, TY-52156 and CAY-1044, and the S1PR1
and S1PR3 inhibitor VPC-23019 efficiently inhibited the passage
of Th17 cells across endothelial cells (Figure 2D), the S1PR1
antagonist W146 did not prevent CD95-mediated Th17 transmi-
gration (Figure 2D). Overall, these findings established that
cl-CD95L promotes a selective Th17 cell transmigration that
partially relies on the increased PSGL-1-E-selectin interactions,
the production of S1P, and the implementation of the S1PR3-
driven signaling pathway.
Cl-CD95L Recruits Th17 Cells In Vivo
To demonstrate in vivo that cl-CD95L is a chemoattractant
for Th17 cells, we injected C57BL/6 mice intraperitoneally
with cl-CD95L and examined infiltrating cells in the peritoneal
cavity, spleen, and mesenteric lymph nodes (MLNs) 12, 24,
and 48 hr later. We evaluated the number of activated CD4+
T cells recruited to these organs in cl-CD95L-injected mice
by using loss of CD62L as an indication of T cell activation.
While the total number of Th1 and Treg cells did not change
in the peritoneal cavity, spleen, or MLNs of cl-CD95L-injected
mice as compared to mice administered control medium
(Figure 3A), Th17 cells accumulated in the peritoneal cavity212 Immunity 45, 209–223, July 19, 2016and, to a lesser extent, in peripheral secondary lymphatic
organs, such as spleen and MLN, of cl-CD95L-injected mice
(Figures 3A and 3B). Real-time quantitative polymerase chain
reaction (qPCR) analysis of key Th17 lineage markers (IL-17,
IL-23R, and C-C chemokine receptor type 6 [CCR6]) of acti-
vated CD4+ T cells confirmed that cl-CD95L recruited Th17
cells to these tissues (Figures S2A and S2C). No increase
was observed in the number of cells expressing IFN-g (indica-
tive of Th1 cells) or FoxP3 (indicative of Treg cells) (Figures
S2D and S2E), confirming that injection of cl-CD95L in the peri-
toneal cavity of immune-competent mice creates a cl-CD95L
gradient that promotes the endothelial transmigration of Th17
cells.
CD95 Triggers a DD-Independent Ca2+ Response
We previously showed that engagement of CD95 evoked a Ca2+
response in activated T lymphocytes, resulting in transient
inhibition of cellular apoptosis (Khadraet al., 2011) andcellmigra-
tion (Malleter et al., 2013; Tauzin et al., 2011). Because of the
instrumental role of the CD95-mediated apoptotic signal in anti-
infectious and anti-tumor responses, we assumed that inhibiting
CD95 non-apoptotic responses while conserving the apoptotic
signal could be an attractive therapeutic option for preventing
Th17 recruitment in inflamedorganswithout altering immune sur-
veillance. We then wondered whether it was possible to selec-
tively inhibit the CD95-mediated Ca2+ response and whether
this blockade could inhibit cell migration without blocking the
apoptotic signal. Human T cells exposed to cl-CD95L rapidly
formed a transient molecular complex containing phospholipase
Cg1 (PLCg1) (Figure 4A). Using a proximity ligation assay (PLA),
we confirmed that this interaction was selective for CD95 and
occurred in a transient and rapid manner (Figure S3A). CD95-
PLCg1 interaction was not detected in CEM-IRC cells, which ex-
pressa faint amountof endogenousCD95 (Be´ne´teauet al., 2008),
and the peak of interaction in parent CEM T cells was reached
5 min after addition of cl-CD95L (Figure S3A). Moreover, the
lack of PLCg1 in T cells resulted in a loss of CD95-mediated
Ca2+ response (Figure S3B). PLA experiments also revealed
that CD95 rapidly recruited PLCg1 in Th17 cells exposed to cl-
CD95L (Figure 4B). We next investigated whether the predomi-
nant DISC components, FADD and caspase-8, might contribute
to CD95-mediated Ca2+ signaling. FADD- and caspase-8-defi-
cient Jurkat T cells (Juo et al., 1998; Juo et al., 1999) exposed
to the cytotoxic CD95L showed no apoptotic signaling (Fig-
ure S3C), but the CD95-mediated Ca2+ signaling pathway re-
mained unaffected in these cells (Figure S3D), suggesting that
PLCg1 activation occurs independently of CD95-DISC and cell
death signaling. To further investigate whether the death domain
(DD) of CD95 was involved in the Ca2+ response, we generated
CD95 constructs devoid of the entire intracellular domain of
CD95 (CD951–175), the DD (CD951–210), or the last 15 aa involved
in FAP-1 protein tyrosine phosphatase recruitment (CD951–303)
(Sato et al., 1995) (Figure 4C). These constructs were expressed
in the CEM-IRC T cell line, which was selected for its low CD95
expression (Figure S3E).
CEM-IRC showed minimal cell death in response to a multi-
meric (dodecamer) and cytotoxic CD95L (IgCD95L, Figure S3F);
however, expression of CD951–303 or wild-type CD95 restored
cell death levels to those observed for parental CEM cells
Figure 2. Transcriptomic Signature in Human Th17 and Treg Cells Stimulated with cl-CD95L
(A) Venn diagram comparing the genes differentially expressed between untreated and cl-CD95L-treated T cell subsets.
(B) Heat map depicting the relative n-fold change in the amount of transcripts significantly (p% 0.05) and differentially expressed between Th17 and Treg cells
stimulated with cl-CD95L (100 ng/mL). Data for each experimental group (n = 2 per condition) are shown. The color gradient indicates n-fold change, as shown.
(C) Pathway enrichment analysis of genes whose expression is significantly modulated by cl-CD95L in Th17 and Treg cells and associated p values.
(D) Left panel: endothelial transmigration of humanTh17 and Treg cellswas evaluated in the presence or absence of cl-CD95L (100 ng/mL) in theBoyden chamber.
Right panel: Th17 cells were pre-treated with FTY720 (1 mM), TY-52156 (10 mM), VPC-23019 (10 mM), W146 (1 mM), or CAY-1044 (1 mM) and then exposed to
cl-CD95L (100 ng/mL), and endothelial transmigration was evaluated via the Boyden chamber. Data represent means ± SD of three independent experiments.(Figure S3F). In contrast, introduction of CD951–175 or CD951–210
failed to induce apoptosis, and as previously observed, these
constructs behaved as dominant-negative receptors (Fig-ure S3F) (Siegel et al., 2000). Furthermore, reconstituting CEM-
IRC cells with wild-type CD95 or CD951–303 restored CD95-
mediated Ca2+ signaling (Figure 4D).Immunity 45, 209–223, July 19, 2016 213
Figure 3. Cl-CD95L Is a Chemoattractant for Th17 Cells In Vivo
Mice received a single injection of cl-CD95L (200 ng/animal) or vehicle and were sequentially sampled.
(A) T cell populations were obtained from tissues or peritoneal cavity washes. Cells were then restimulated in the presence of PMA and ionomycin for 4 hr and then
analyzed by flow cytometry. Cells were identified as follows; Th1 (CD4+IFN-g+), Th17 (CD4+IL-17+), and Treg (CD4+Foxp3+). Numbers of infiltrating cells were
calculated.
(B) Ratios of Th17/Th1 cells per organ were determined 24 hr after injection. Data represent two independent experiments with six mice/group; means ± SEM are
displayed.Whereas the loss of the DD from the CD951–210 construct pre-
vented apoptotic signaling, CD95-DD deletion did not affect
induction of Ca2+ signaling (Figure 4D). Given that a CD95
construct devoid of the entire intracellular region (CD951–175)
failed to evoke a Ca2+ response, we concluded that Ca2+
signaling was triggered by CD95 amino acids 175–210.
We next examined whether CD951–210 was capable of recruit-
ing PLCg1. To this end, we transiently co-transfected HEK214 Immunity 45, 209–223, July 19, 2016cells with GFP-fused CD95 constructs and wild-type PLCg1.
Although the transfected cells expressed similar quantities of
CD95-GFP chimeric constructs at the cell surface (Figure S3G),
PLCg1 was absent only from the CD951–175 immunoprecipitate
(Figure 4E). To demonstrate that amino acid residues 175–210
of CD95 contribute to PLCg1 recruitment, we generated a
construct comprising CD95175–210 (termed the calcium-inducing
domain [CID]) fused to the fluorescent protein mCherry. Unlike
mCherry alone, CD95175–210-mCherry interacted with PLCg1
and inhibited its recruitment to CD95 (Figure S3H), suggesting
that interference with this juxtamembrane domain might prevent
CD95-mediated Ca2+ signaling.
To confirm this hypothesis, we synthesized a cell-pene-
trating peptide, TAT-CID, by linking CID to the nine-amino-
acid HIV-TAT sequence (Figure S4A), which serves as a carrier
for protein translocation across the plasma membrane (Vive`s
et al., 1997). Pre-incubation of activated peripheral blood lym-
phocytes (PBLs) with TAT-CID impaired the recruitment of
PLCg1 (Figure 4F) and abolished the induction of CD95-medi-
ated Ca2+ signaling (Figure 4G). Similarly, pre-incubation of
CEM cells with TAT-CID inhibited PLCg1 binding to CD95 (Fig-
ure S4B) and abrogated the CD95-induced Ca2+ response in
Jurkat and CEM T cell lines (Figure S4C). TAT-CID also
reduced Akt phosphorylation at serine 473 (a hallmark of
PI3K signaling activation) in cl-CD95L-exposed PBLs (Fig-
ure S4D), confirming a role of calcium in the modulation of
the PI3K signaling pathway (Malleter et al., 2013). Neverthe-
less, although TAT-CID impeded CD95-mediated Ca2+ and
PI3K signaling, the peptide did not affect the apoptotic
signaling pathway (Figure S4E). Hence, we mapped a domain
in the CD95 receptor, namely CID, which recruits PLCg1 and
elicits Ca2+ responses.
CID Interacts with the SH3 Domain of PLCg1
To address whether CD95 directly interacts with PLCg1, we
performed a Renilla luciferase-based protein fragment comple-
mentation assay (RLuc-PCA) (Stefan et al., 2007). The Renilla
luciferase enzyme was divided into two fragments. Each frag-
ment (F1 and F2) was fused to various CD95 and PLCg1
domains and co-transfected in HEK cells (Figures S5A–S5D).
The PLCg1-SH3 interacted with both the whole CD95 intracel-
lular region and CD95-CID, but it failed to reconstitute enzyme
activity when combined with CD95-DD (Figures 5A and 5B).
To strengthen this result, we evaluated whether the cell-pene-
trating TAT-CID peptide could inhibit the interaction of PLCg1-
SH3 with CD95-CID. Although TAT-control peptide did not alter
luciferase activity in cells co-expressing PLCg1-SH3-F1 and
CD95-CID-F2, TAT-CID efficiently blocked this activity in a
dose-dependent manner (Figure 5C), supporting the hypothesis
that CD95 directly associates with PLCg1 through the CD95-
CID domain. Intriguingly, SH3 domains primary bind to peptides
containing a consensus PxxP sequence that is not present in
CID; however, many examples of unconventional SH3-binding
peptides have previously been described (Saksela and Permi,
2012).
To understand howCD95 CIDmight interact with PLCg1-SH3,
we undertook two computational peptide screenings. First, we
performed homology modeling by using the crystal structure
of PLCg1-SH3 in association with the SLP-76 heptapeptide
complex (PDB:1YWO) (Deng et al., 2005). This structure served
as a template, and the SLP-76 peptide was replaced by each
heptapeptide combination present in CD95-CID. Second, we
took a protein-peptide docking approach by using each
aforementioned CID heptapeptide alternatively docked within
the PLCg1-SH3 domain. Both methods predicted that amino
acids 182–188 (TCRKHRK) would have the highest affinity for
PLCg1-SH3, and the calculated binding energy of the complexconsisting of PLCg1-SH3 and TCRKHRK was similar to that of
the PLCg1-SH3 interaction with SLP-76 (Figure 5D and Table
S3). To prove that the TCRKHRK amino acid sequence corre-
sponded to the minimal domain interacting with PLCg1, we first
used RLuc-PCA and performed an alanine-scanning experi-
ment. This confirmed that amino acid residues R184, K185,
and K188 were instrumental in the interaction of CD95 with
PLCg1 (Figure S5E). In agreement with this cell-based assay,
our computer model identified an interaction between R184 gua-
nidine and SH3-PLCg1 through a hydrogen-bond network
involving the side chains of Y845 and Q805 and the backbone
of K803. K185 amine function forms hydrogen bonds, in an intra-
molecular manner, with the H186 and G826 backbones of
SH3-PLCg1. A salt bridge occurred between K188 and E825.
Furthermore, the positioning of K188 in the SH3 cavity required
the displacement of a water molecule (H2O105 observed in the
crystal structure), an entropically favorable process. For this sol-
vent-exposed interface, the methylene chain of these basic
residues forms extensive van der Waals contacts with the SH3
hydrophobic shallow pockets. Overall, these observations indi-
cated that even if the CID sequence is not related to a typical
class II ligand of SH3, it complies with its properties in terms of
van der Waals interactions (Deng et al., 2005). Of note, RLuc-
PCA also revealed that glutamic acid 189, localized outside the
minimal TAT-CID domain, participated in the binding of CD95
with PLCg1 (Figure S5E). This amino acid may play a role of
‘‘compass residue’’ evoked for typical proline-rich SH3 ligands
(Musacchio, 2002). Indeed, the canonical PxxP motif-containing
peptides could be docked in two opposite orientations regarding
the relative positioning of a positively charged residue (+xxPxxP
or xPxxPx+) interacting with a negatively charged cleft on the
SH3 surface (Saksela and Permi, 2012). Similarly to this basic
amino acid in the PXXP motif, E189 could contribute to the posi-
tioning of the minimal CD95-CID peptide in the PLCg1 SH3
domain.
Second, we generated two constructs, CD95 in which R184
and K185 were replaced by alanine (double mutant, or DM)
and CD95 in which R184, K185, and K188 were replaced by
alanine (triple mutant, or TM). These two constructs and wild-
type CD95 were transfected into HEK cells, and the CD95-medi-
ated Ca2+ response was evaluated in these cells. HEK cells ex-
press endogenous wild-type CD95, and therefore we expected
expression of our constructs to create heterotrimeric complexes
consisting of wild-type and mutated CD95, which could inhibit
PLCg1 recruitment in a dominant-negative fashion. Both double
and triple mutants abrogated the CD95-mediated Ca2+ signaling
pathway (Figure S5F). For each amino acid, we also generated
single mutatants. Strikingly, when expressed in HEK cells,
these mutants did not alter the CD95-mediated Ca2+ signaling
pathway (data not shown), suggesting that unlike double and
triple mutations, a single mutation inside the minimal CID did
not disrupt PLCg1 recruitment. Because CID corresponds to a
disorganized domain, we surmised that increasing PLCg1 bind-
ing affinity requires a larger zone of contact and that elimination
of only one amino acid might not be sufficient to impair this
recruitment in a heterotrimeric complex containing wild-type
CD95. Overall, these findings indicate that the CD95-CID
amino-terminal region corresponds to an unconventional SH3-
binding peptide.Immunity 45, 209–223, July 19, 2016 215
Figure 4. CD95 Induces a DD-Independent Ca2+ Response
(A) CEM T cells were stimulated with cl-CD95L (100 ng/mL). Cells were lysed, and CD95 was immunoprecipitated. The protein complex was resolved by SDS-
PAGE and subjected to immunoblotting. Total lysates served as controls. The columnmarked ‘‘B’’ indicates treatment with beads alone. Data are representative
of three independent experiments.
(B) Left panel: Th17 cells from peripheral blood were stimulated with cl-CD95L (100 ng/mL) for indicated times. PLA was performed with anti-CD95 and anti-
PLCg1 mAbs. Nuclei were stained in blue (DAPI). Red dots were observed when the distance between anti-CD95 and anti-PLCg1 mAbs was close (z16 nm).
Right panels: Red dots were counted in 200 cells taken from different fields. Data represent means ± SD of three independent experiments.
(C) Schematic diagram of CD95 constructs.
(legend continued on next page)
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Figure 5. CID Interacts with the SH3 Domain
of PLCg1
(A) The intracellular region of CD95 (amino acids
175–319) fused to F2 was co-transfected into HEK
cells with the indicated domains of PLCg1 fused
to F1. Refolding of the luciferase and reconstitution
of enzyme activity revealed protein/protein in-
teractions. Data represent means ± SD of three
independent experiments.
(B) The PLCg1-SH3 domain (amino acids 790–851)
fused to F1 was co-transfected into HEK cells
with the indicated regions of CD95 fused to F2,
and luminescence was assessed. Data represent
means ± SD of three independent experiments.
(C) CD95-CID-F2 and PLCg1-SH3-F1 were co-
transfected into HEK cells. Transfected cells were
pre-incubated for 1 hr with TAT-control (50 mM) or
TAT-CID (50 and 10 mM), and luminescence was
measured.
(D) Predicted interaction between CID and PLCg1.
Within CD95-CID, TCRKHRK is the amino acid
sequence that is optimal for interaction with
PLCg1-SH3.
(E) Indicated cells were pre-incubated for 1 hr
with TAT-control, TAT-CID, TAT-CID-N, or TAT-
CID-C (10 mM) and then stimulated with cl-CD95L
(100 ng/mL). [Ca2+]CYT was assessed in FuraPE3-
AM (1 mM)-loaded cells. Data represent means ±
the SD of three independent experiments.To confirm our in silico result, we synthesized two cell-pene-
trating peptides consisting of the amino- and carboxyl-terminal
regions of CD95 CID (CID-N, corresponding to aa 175–192,
and CID-C, corresponding to aa 193–210) (Figure S5G).
We then evaluated their effects on the CD95-mediated Ca2+
response (Figure 5E), and showed that only CID-N abrogated
CD95-mediated Ca2+ signaling in Jurkat cells and activated
PBLs (Figure 5E). Taken together, these findings demonstrated
that the juxtamembrane region of CD95 directly interacts with
PLCg1-SH3 to evoke Ca2+ signaling.
Lastly, we examined whether the inhibitory actions of TAT-CID
were selective for CD95-mediated Ca2+ signaling. Although
T cell receptor (TCR) stimulation led to a PLCg1-dependent
Ca2+ response in Jurkat cells (Figure S5H), pre-treatment with(D) CEM-IRC cells expressing GFP alone or the GFP-fused CD95 constructs shown in (C) were loaded w
stimulated with cl-CD95L (100 ng/mL; arrow), and the intracellular calcium concentration ([Ca2+]i) was mon
periments performed independently on n = 20 cells.
(E) HEK cells transfected with the indicated constructs were stimulated with CD95L (100 ng/mL) for indica
noprecipitated from cell lysates and subjected to immunoblotting, as indicated. Total lysates served as contro
beads alone. Data are representative of three independent experiments.
(F) Activated PBLs were pre-incubated for 1 hr with TAT-control or TAT-CID (10 mM) and stimulated with cl-CD
protein complex was immunoprecipitated from cell lysates and subjected to immunoblotting, as indicated. T
‘‘B’’ indicates a treatment with beads alone. Data are representative of three independent experiments.
(G) Activated PBLs from healthy donors were loaded with FuraPE3-AM (1 mM) and pre-treated for 1 hr with TA
with cl-CD95L (100 ng/mL; arrow). Data represent means ± SD.the TAT-CID peptide had no such effect
(Figure S5I). Similarly, TAT-CID did not in-
fluence the PLCb-driven Ca2+ response
stimulated by carbachol, a cholinergic
agonist that activates G-protein-coupledreceptors to release calcium (Figure S5J). Therefore, TAT-CID
selectively inhibits CD95-mediated Ca2+ signaling.
Inhibition of CD95-Mediated Ca2+ Signaling Prevents
Th17 Cell Transmigration In Vivo
To assess the potential of TAT-CID as a therapeutic agent for
SLE patients, we first examined its effect on Th17 cell transmi-
gration. Figure 6A shows that TAT-human CID (TAT-hCID)
dose dependently inhibited CD95-mediated endothelial transmi-
gration of human Th17 cells. Alignment of the human and mouse
CD95 protein sequences highlighted differences in the CID re-
gion (21.2% sequence identity) (Figure S6A). We reconsti-
tuted human CEM-IRC cells with mouse CD95 (Figure S6B).
CD95-mediated apoptotic signaling was restored in the mouseith the Ca2+ probe, Fluo2-AM (1 mM). Cells were
itored. Data are given as means ± SD of three ex-
ted times. The CD95 protein complex was immu-
ls. The columnmarked ‘‘B’’ indicates treatment with
95L (100 ng/mL) for the indicated times. The CD95
otal lysates served as controls. The column marked
T-control or TAT-CID (10 mM). Cells were stimulated
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Figure 6. TAT-CID Alters Immunological Parameters in Lupus-Prone Mice
(A) Transmigration of mouse Th17 cells was monitored with the indicated concentrations of TAT-CID.
(B–D) C57BL/6 mice were injected with TAT-control or TAT-CID (40 mg/kg) 2 hr prior to intraperitoneal injection of cl-CD95L (200 ng) or vehicle. Animals were
examined 24 hr after cl-CD95L injection.
(B) Total cell counts in the peritoneal cavity are shown.
(C) PECs were subjected to magnetic bead separation to identify the percentage of infiltrating CD4+CD62L (activated) T cells.
(D) IL-17A concentrations in the peritoneal cavity were measured via ELISA (two-way ANOVA). Data in (B)–(D) represent two independent experiments performed
with six mice/group. Data are means ± SEM.
(E–I) MRL.Faslpr/+ mice received either TAT-CID or TAT-control for 5 weeks. (E) Upon completion of the experimental protocol, ratios of spleen weight to body
weight of individual animals were measured and compared to those of age-matched MRL and homozygous MRL.Faslpr/lpr mice. (F) Total cell number in the
spleen is shown. (G) Cellular composition of the spleen was determined in regard to the number of CD4+CD62L T cells. (H) mRNA expression levels of il-23r,
ccr6, and ror-gt in cells from (C). (I) Isolated T cells from (G) were re-stimulated with anti-CD3 mAb for 72 hr. IL-17A was then quantified by ELISA (unpaired
Student’s t test).CD95-expressing cells, but not in the parental CEM-IRC cells
(Figure S6B). TAT-mouse CID (TAT-mCID), but not TAT-hCID,
inhibited the mouse CD95-mediated Ca2+ response (Figures
S6C and S6D). Similarly, TAT-mCID also inhibited the CD95-
mediated Ca2+ response in mouse T lymphocytes (Figure S6E),
indicating that despite differences in the human and mouse
CD95-CID sequences, both domains trigger Ca2+ signaling.
We next injected C57Bl/6 mice with TAT-control or TAT-mCID
prior to the intraperitoneal injection of cl-CD95L and then deter-218 Immunity 45, 209–223, July 19, 2016mined the number of T cells infiltrating the peritoneal cavity 24 hr
later. TAT-mCID treatment reduced the CD95-mediated accu-
mulation of peritoneal exudate cells (PECs) (Figure 6B) and
CD4+ lymphocytes (Figure 6C). In agreement with the data
shown in Figure 3, cl-CD95L injection increased IL-17 levels in
the peritoneal cavity, but the increase was overturned by TAT-
mCID pre-treatment (Figure 6D). These findings indicated that
TAT-CID inhibits cl-CD95L-mediated recruitment of IL-17-
secreting CD4+ T cells in vivo.
TAT-CID Alleviates Clinical Outcomes in Lupus-Prone
MRL.Faslpr/+ Mice
Patients suffering from ALPS type Ia exhibit CD95mutations that
cause SLE-like autoimmunity (Drappa et al., 1996; Fisher et al.,
1995; Rieux-Laucat et al., 1995). Because of the insertion of
a retrotransposon into intron 2 of the CD95 gene, heterozygous
MRL.Faslpr/+ mice express reduced levels of CD95 and develop
lupus (Adachi et al., 1993). T cells from both ALPS type Ia
patients and MRL.Faslpr/+ mice show loss of sensitivity to
CD95-mediated apoptosis but retain normal activation of non-
apoptotic signaling pathways (Legembre et al., 2004). We asked
whether the implementation of CD95-mediated non-apoptotic
signaling pathways in lupus-prone mice contributed to symp-
tom severity. Because TAT-CID inhibited CD95-mediated Ca2+
response without affecting apoptotic signaling (Figures S4C–
S4E), this peptide allowed us to address this question.
TAT-mCID and TAT-control peptides were administered to
MRL.Faslpr/+ heterozygote mice. After completion of the trial, an-
imals were sacrificed, revealing an alleviation of splenomegaly in
TAT-CID-treated mice relative to controls (Figure 6E), without
any negative effect onwhole-bodyweight (Figure S6F). Likewise,
TAT-CID significantly reduced the weights of the inflamed kid-
neys and themesenteric lymph nodes (Figure S6G). Examination
of the cellular composition of the spleen in MRL.Faslpr/+ mice re-
vealed a significant decrease in total spleen cell number (Fig-
ure 6F) and activated CD4+ T cells (Figure 6G), but not B cells
(Figure S6H). Additionally, TAT-CID significantly decreased
Th17 cell infiltration in the spleen of TAT-CID- versus TAT-con-
trol-treated mice, as indicated by reduced expression levels of
Ccr6 and Il23r, and to a lesser extent Rorc, three key molecular
markers of Th17 cells (Figure 6H). Re-stimulation of spleen-infil-
trating CD4+ T cells confirmed that the immune cells failed to
produce IL-17A in TAT-CID-treated mice (Figure 6I).
Examination of the kidneys inMRL.Faslpr/+mice demonstrated
that TAT-CID versus TAT-control decreased cell infiltration (Fig-
ures 7A–7C). The reduction in cellular infiltration in TAT-CID-
treatedMRL.Faslpr/+mice translated to a reduction of glomerulus
damage (Figures 7D–7F). The number of cells infiltrating the
glomeruli was significantly lower in TAT-CID-treated mice than
in TAT-control mice, resulting in significant swelling and loss
of shape of the glomeruli in these latter mice (Figure 7D versus
Figure 7E). Moreover, improvement of the kidney architecture
in TAT-CID-treated mice (Figure 7F) was associated with a
decreased deposition of C3 activation fragments when these
mice were compared to TAT-control mice (Figure 7G). Accord-
ingly, organ function was restored in mice treated with repeated
injections of TAT-CID as compared to TAT-control-treated mice
with reduction of blood concentrations of creatinine and urea
(Figure 7H). In parallel, serum concentrations of anti-dsDNA
IgG1 were lower in TAT-CID mice than in TAT-control-treated
MRL.Faslpr/+ mice (Figure 7I). When kidneys of TAT-CID and
TAT-control treated Lpr+/ mice were analyzed, we found a
lower number of CD4+IL17+ cells in the TAT-CID group than in
the TAT-control-treated mice (Figure 7J). Although CD4+IFN-g+
cell number tended to be lower in TAT-CID treated mice than
in control mice, this effect was non-significant (Figure 7J). Treat-
ment efficiency supported our prediction that CD95-induced
non-apoptotic signaling pathways contribute to lupus severity
and progression.DISCUSSION
An initial study showing that activated T cells transmigrated in
the presence of cl-CD95L through the implementation of PI3K
and Ca2+ signaling pathways (Tauzin et al., 2011) raised the
question of whether all T cells responded similarly to cl-CD95L
and whether it was possible to selectively inhibit the CD95-medi-
ated pro-inflammatory signaling pathway without affecting the
apoptotic cues. Although the death domain of CD95 is instru-
mental in the induction of the PI3K signaling pathway (Tauzin
et al., 2011), we here provided evidence that the Ca2+ response
stemmed from a different CD95 region, which we identified and
designated calcium inducing domain (CID).
CD95L+ blood vessels in skin of SLE patients were surrounded
by infiltrating immune cells, suggesting that these structures
could serve as ‘‘gateways’’ for inflammatory leukocytes and
the ensuing recruitment of Th17 cells. By contrast, a recent study
showed that CD95L expressed on endothelial cells functions to
eliminate CD8+ T cells and in doing so, prevents effective anti-tu-
mor immunity (Motz et al., 2014). Examination of the CD8+ T cell
infiltrate surrounding CD95L+ blood vessels in SLE patients re-
vealed no inverse correlation between CD95L expression and
the number of infiltrating CD8+ T cells (Figures S7A and S7B).
Given that CD95L exerts its chemoattractant activity only after
cleavage by metalloproteases (Tauzin et al., 2011), the observed
discrepancy between the amount of immune infiltrate surround-
ing CD95+ blood vessels in cancer subjects and SLE patients
might be explained by the absence or presence of an as-yet-un-
identified CD95L-processing metalloprotease.
The aggravation of SLE by cl-CD95L thus appears to involve a
two-step mechanism. First, selective recruitment of Th17 and
Th1 cells, conserved in both mouse and humans, occurs at the
expense of Treg cell recruitment and might advance inflamma-
tion in damaged SLE organs. Second, Th17 cells exposed to
cl-CD95L upregulate their expression of the PSGL-1 adhesion
molecule. Not only does PSGL-1 promote tethering of lympho-
cytes to endothelial cells and subsequent rolling, but its high
expression levels in T cells also provoke the secretion of effector
cytokines (Baaten et al., 2013).
Of interest, the cellular balance between ceramide (apoptotic)
and S1P (survival) is crucial for cell fate (Cuvillier et al., 1996), and
although the interplay between CD95 and ceramide synthesis is
well known and contributes to the induction of the cell-death pro-
gram (Cifone et al., 1994), our findings provide evidence that a
molecular link also exists between CD95 stimulation and activa-
tion of the S1P signaling pathway. Furthermore, activation of the
S1P signaling pathway by cl-CD95L furnishes amolecular mech-
anism that can explain how T cells and, more specifically, Th17
cells migrate in presence of this naturally processed ligand.
Based on our study and recent data from Yosef and colleagues,
who used transcriptional profiling to reveal a role for CD95
in Th17 differentiation (Yosef et al., 2013), we conclude that
CD95L/CD95 signals play a pivotal role in autoimmunity, and
not only through a canonical apoptotic role.
We employed complementary approaches to reveal that
CD95-CID directly interacts with the PLCg1-SH3 domain to
implement a Ca2+ signal. Linker for activation of T cells (LAT) is
a critical adaptor molecule required for TCR-mediated Ca2+
responses. Upon TCR engagement, LAT recruits PLCg1 via itsImmunity 45, 209–223, July 19, 2016 219
Figure 7. TAT-CID Alleviates Clinical Disease in Lupus-Prone Mice
MRL.Faslpr/+ mice received either TAT-CID or TAT-control twice weekly for 5 weeks. Kidneys were fixed, sectioned, and stained with hematoxylin and eosin. All
images were captured at 203 ([B]; scale bar represents 250 mm) or 403 ([A, D, and E]; scale bar represents 150 mm) magnification.
(A) Representative section of the vasculature (V) in a TAT-CID-treated mouse, with no obvious cellular infiltrate surrounding the border (delineated by the dashed
black line).
(B) Cellular infiltrate surrounding the vasculature (V) in a TAT-control-treatedmouse, with multiple cell layers observed adjacent to the vasculature border (dashed
black line).
(C) Vascular infiltrate scores were calculated for the kidneys in TAT-CID- and TAT-control-treated mice. Data represent means ± SD (n = 8 mice/group; one-way
ANOVA).
(D) Kidney tissue showing normal glomeruli (arrow) and an adjacent tubule in TAT-CID-treated mice.
(E) Kidney tissue showing pathological modifications (arrows) to the glomeruli in TAT-control-treated mice.
(F) Glomerular-damage scores were calculated for each kidney in TAT-CID- and TAT-control-treated mice. Data represent means ± SD (n = 8 mice/group;
***p < 0.001; Student’s t test).
(G) C3 complement accumulation in kidneys of TAT-CID and TAT-control-treated MRL.Faslpr/+ mice was assessed by microscopy. Inset: pictures of nucleus
(DAPI) and C3 staining in mouse kidneys.
(H) Serum creatinine (upper panel) and urea (lower panel) were measured.
(I) Anti-dsDNA IgG1 amounts were determined by ELISA. Data represent means ± SD (n = 8 mice/group; Student’s t test).
(J) Immunohistochemistry staining of IFN-g or IL-17. Cytokine-positive cells were counted in treated kidneys.SH2 domains (Zhang et al., 2000). CD95 and TCR therefore re-
cruit PLCg1 through different domains, and TAT-CID failed to
inhibit TCR-mediated Ca2+ signaling in the current study. More-220 Immunity 45, 209–223, July 19, 2016over, blockade of CD95-mediated Ca2+ signaling by TAT-CID
not only prevented selective recruitment of Th17 cells to the peri-
toneal cavity of cl-CD95-injected mice but also lessened clinical
symptoms in heterozygous MRL.Faslpr/+ mice. These observa-
tions implicate TAT-CID as an attractive therapeutic molecule
with high selectivity toward the CD95-mediated Ca2+ signaling
pathway.
Cl-CD95L induces the transient (within minutes) recruitment
of PLCg1. The CD95 domain encompassing amino acids 175–
210 has never been crystallized, probably because this region
corresponds to an intrinsically disordered region (IDR) that lacks
a unique three-dimensional structure. We conducted several
molecular-dynamics experiments to confirm that this peptide
has very low propensity, if any, for folding (Figures S7C and
S7D). Numerous examples of transient protein/protein interac-
tions involving IDRs are now documented, indicating the impor-
tance of IDRs in allowing proteins to briefly associate with a large
number of partners so as to dynamically modulate cell signaling
(Cumberworth et al., 2013). This molecular feature is consistent
with the CD95-CID-mediated induction of a rapid and transient
Ca2+ response that promotes cell migration via the MISC
formation.
A recent phase I/II clinical trial demonstrated that a decoy
CD95 receptor, APG101, could impede CD95/CD95L interaction
and benefited patients suffering from glioblastoma (Tuettenberg
et al., 2012). Although APG101 might be of short-term therapeu-
tic benefit to lupus patients, its inability to discriminate between
the anti-tumor/infectious (i.e., apoptotic signaling) and pro-in-
flammatory actions of CD95 might lead to unexpected adverse
events.
Because we have found that inhibiting the CD95-mediated
Ca2+ response does not interfere with apoptotic signaling,
we propose that selective blockade of CD95-mediated Ca2+
signalingmight open new therapeutic avenues for SLE treatment
in the future. Moreover, given the selective effect of cl-CD95L on
Th17 cell recruitment, we also propose that downregulating Ca2+
signaling could lessen the inflammatory activity of Th17 cells in
other chronic inflammatory disorders.
EXPERIMENTAL PROCEDURES
Antibodies and Other Reagents
See Supplemental Experimental Procedures.
Plasmids and Constructs
All constructs and primer pairs used are described in the Supplemental
Information.
T Cell Subset Isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy-coat
by density gradient via lymphocyte separation medium (Eurobio). PBMCs
were then subjected to selection with a cocktail of antibody-coated magnetic
beads: CCR6+CXCR3CD4+ cells (Th17 cells) were sorted with Human Th17
Enrichment kit (STEMCELL Technologies), and CD4+CD25+CD127 Treg cells
were isolated with MACS column (Miltenyi Biotec).
Transcriptomic Analysis
Isolated Th17 and Treg cells from two healthy donors were treated with
or without 100 ng/mL of cl-CD95L for 8 hr. Total RNA was extracted with
the Nucleospin RNA XS kit (Macherey-Nagel), and quality was assessed
with the RNA6000 nano chip (Agilent). For each condition, 9 ng of RNA
was reverse transcribed with the Ovation PicoSL WTA System V2 (Nugen,
Leek, The Netherlands). Fragmented cDNAs were hybridized to GeneChip
Human Gene 2.0 ST microarrays (Affymetrix). Then chips were scanned on a
GeneChip Scanner 3000 7G (Affymetrix). Raw data and quality-control metricswere generated from scanned images using the Expression Console software
(Affymetrix).
Probes were mapped with Brainarray V20 CDF files (http://brainarray.mbni.
med.umich.edu/) and normalized by robust multi-array averaging with R soft-
ware. Statistical analyses were performed with Partek Genomics Suite; a
p value % 0,05 was considered significant. Pathway enrichment analyses
were generated with Ingenuity Pathway Analysis (QIAGEN).
MRL.Faslpr/+ Mouse Treatment
MRL.Faslpr/+ mice were obtained from the Jackson Laboratory and back-
crossed onto aMRL background. Females (n = 8/group) were intraperitoneally
administrated with either TAT-CID or TAT-Ctrl peptides (40 mg/kg) starting at
8 weeks of age, twice weekly for 5 weeks. After re-stimulation of CD4+ cell
populations with anti-CD3, cell culture supernatants were dosed for IL-17A
and IFN-g by ELISA, and qPCR analysis of purified cell population was also
performed as mentioned above. Kidneys were fixed into 4% PFA overnight
prior to being placed in ethanol, sectioned, and stained. Scoring was con-
ducted by an individual blind to the objective/treatments within the study as
per (Kikawada et al., 2003). FITC-conjugated rabbit anti-C3 polyclonal anti-
body (Dako) and nuclei (DAPI, sigma-aldrich) staining was performed on frozen
kidney sections, and results were analyzed with NIKON Ni-E (magnification 3
200). C3 accumulation in kidneys was assessed by densitometric analysis of
ten different fields via NIS-Elements AR Analysis software.
Transendothelial Migration of Activated T Lymphocytes
Membranes (3 mm pore size) of a Boyden chamber were hydrated in sterile
D-PBS (Millipore). Activated T-lymphocytes (106) were added to the top cham-
ber on a confluent monolayer of HUVEC in a low-serum (1%) medium. The bot-
tomchamberwasfilledwith low-serum(1%)mediumin thepresenceorabsence
of100ng/mlofcl-CD95L. Inexperimentsusinghumansera,500ml of serumfrom
either healthy donors or SLE patients was added to the lower chamber. Cells
were cultured for 24 hr at 37C in a 5% CO2, humidified incubator. Transmi-
grated cells were counted in the lower reservoir by flow cytometry with a
standard of 2.53 104 fluorescent beads (Flow-count, Beckman Coulter).
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